Pharmaxis Science Update Outlines Scope for Anti-Fibrotic Pipeline

30th Oct 19

Release Date: 30/10/2019 8:22am

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today provided an update on the company’s anti-fibrotic drug pipeline highlighting both the therapeutic areas of interest and competitive positioning of its LOXL2 and pan LOX inhibitors.

Speaking at the 2019 AusBiotech conference in Melbourne, Australia, Pharmaxis CEO Gary Phillips outlined the steps Pharmaxis has taken to develop a best in class status for its Lysyl oxidase like 2 (LOXL2) inhibitors and strong pre-clinical data in myelofibrosis for its pan-LOX inhibitor PXS-5505.

Read full media release - pdf

Categories: News and Media